Page last updated: 2024-08-21

pyrazines and Hepatitis C

pyrazines has been researched along with Hepatitis C in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's1 (20.00)29.6817
2010's2 (40.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Akagi, Y; Fujioka, S; Inaba, T; Ito, S; Kinoshita, W; Komoda, Y; Kondo, K; Maeda, K; Nakamura, H; Okuda, S; Tamatani, Y; Terui, T; Ukaji, Y1
Abdurakhmanov, E; Belfrage, AK; Brandt, P; Danielson, UH; Gising, J; Kerblom, E; Neyts, J; Oshalim, A; Sandström, A; Skogh, A1
Birkenbach, M; Constantinescu, S; Daller, JA; Gillespie, A; Karachristos, A; Lee, I; Leech, S; Sifontis, NM; Silva, P; Swami, A1
Cho, SH; Choi, JY; Chon, CY; Han, JY; Jang, JJ; Jang, JW; Kim, SG; Kim, YM; Lee, DH; Lee, YS; Um, SH; Yu, E1
Matsumori, A1

Reviews

1 review(s) available for pyrazines and Hepatitis C

ArticleYear
Cytokines in myocarditis and cardiomyopathies.
    Current opinion in cardiology, 1996, Volume: 11, Issue:3

    Topics: Animals; Cardiomyopathy, Dilated; Cardiotonic Agents; Cytokines; Heart Injuries; Hepatitis C; Humans; Mice; Mice, Mutant Strains; Myocarditis; Pyrazines; Quinolines

1996

Trials

1 trial(s) available for pyrazines and Hepatitis C

ArticleYear
Oltipraz therapy in patients with liver fibrosis or cirrhosis: a randomized, double-blind, placebo-controlled phase II trial.
    The Journal of pharmacy and pharmacology, 2011, Volume: 63, Issue:5

    Topics: Adult; Anticarcinogenic Agents; Biomarkers; Biopsy; Collagen; Double-Blind Method; Female; Hepatitis B; Hepatitis C; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Pyrazines; Thiones; Thiophenes; Transforming Growth Factor beta1

2011

Other Studies

3 other study(ies) available for pyrazines and Hepatitis C

ArticleYear
Orally bioavailable HCV NS5A inhibitors of unsymmetrical structural class.
    Bioorganic & medicinal chemistry letters, 2020, 09-01, Volume: 30, Issue:17

    Topics: Administration, Oral; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Mutation; Pargyline; Pyrazines; Structure-Activity Relationship; Viral Nonstructural Proteins; Virus Replication

2020
Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease.
    Bioorganic & medicinal chemistry, 2016, 06-15, Volume: 24, Issue:12

    Topics: Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Molecular Docking Simulation; Point Mutation; Protease Inhibitors; Pyrazines; Viral Nonstructural Proteins

2016
Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line?
    Clinical transplants, 2009

    Topics: B-Lymphocytes; Boronic Acids; Bortezomib; Creatinine; Follow-Up Studies; Graft Rejection; Hepatitis C; Humans; Immunity, Cellular; Immunity, Humoral; Immunoglobulins, Intravenous; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Protease Inhibitors; Pyrazines; T-Lymphocytes

2009